US vaccine panel to discuss waning effectiveness, new shots

October 24, 2017 by Mike Stobbe
US vaccine panel to discuss waning effectiveness, new shots
This Jan. 10, 2013 file photo shows vials of flu vaccines in Philadelphia. No vaccine is perfect, and it can take many years to find out how well a new vaccine works and how long it lasts. The annual flu vaccine is a particularly hard one to nail. The virus changes quickly and spreads easily. U.S. health officials make their best guess each spring about the formula for the next flu season. (AP Photo/Matt Rourke, File)

Two years ago, George Green got stabbing pain and bad blisters around his right arm. It was the worst case of shingles his doctor had ever seen.

"I said, 'Wait a minute, I had the vaccine! How come I got this?'" recalled Green, a 68-year-old engineer in Austell, Georgia, who got the shot seven years earlier.

His doctor at Emory University, Dr. Sharon Bergquist, said about 10 percent of the patients she's given the shingles shot have come back with the disease years later.

No vaccine is perfect, and it can take many years to find out how well a new vaccine works and how long it lasts. Sometimes, health officials have called for an additional dose when it became clear the first round wasn't cutting it. But disappointing performance is also prompting drugmakers to pursue new vaccines for older patients, using new additives to boost effectiveness.

The issue of waning protection is expected to be discussed when the Advisory Committee on Immunization Practices meets in Atlanta. The two-day meeting opens Wednesday. The federal panel of experts recommends what vaccines children and adults should receive and when.


The annual flu vaccine is a particularly hard one to nail. The virus changes quickly and spreads easily. U.S. health officials make their best guess each spring about the formula for the next flu season. In four of the last seven seasons, the flu vaccine didn't work much at all in people 65 and older, who can be hit hard by the flu because of weaker immune systems. Some doctors wonder whether those seniors who get a shot in September need another dose in January to protect them through the flu season—a question that hasn't been well studied, said Dr. William Schaffner, a Vanderbilt University vaccine expert who works with the committee. There's a relatively new vaccine for over 65 that includes an immune-boosting additive, but it hasn't been around long enough to know exactly how well works.

The vaccine panel will hear an update about a nasal-spray version of flu vaccine that it stopped recommending after health officials said it wasn't working in U.S. kids.


Mumps is best known for causing puffy cheeks, but sometimes can lead to hearing loss, meningitis and even loss of sterility. A mumps vaccine has been part of routine childhood shots for nearly five decades. Yet, there were 5,300 cases reported in the U.S. last year—the most in a decade—and so far the numbers this year are not far off. Illnesses in vaccinated people tend to be less severe, health officials say. Still, research suggests that 10 or more years after the second childhood dose, protection against the virus fades enough to help outbreaks take hold.

The federal panel is not expected to propose a third dose for all kids, but is talking about endorsing an extra shot where an outbreak occurs.


The hepatitis B virus can destroy the liver and lead to death. New infections fell after vaccines became widely available in the 1980s and were later included in childhood shots. It is spread through contact with blood or other bodily fluids, and the vaccine is also recommended for some adults. Experts have noted signs of faltering protection, particularly in diabetics and older adults. Outbreaks in nursing homes and assisted living facilities have been a recurring problem.

Dynavax Technologies Corp. has developed an adult vaccine called Heplisav-B, which also uses a new additive. The shot showed impressive levels of protection in studies, but the Food and Drug Administration is seeking more information before deciding whether to approve it. The vaccine panel is expected to discuss it but doesn't take a recommendation vote until a vaccine is licensed.


Anyone who has had the chickenpox can get shingles, a painful condition that causes blisters, when the chickenpox virus resurfaces decades later. Merk's Zostavax has been available for about a decade and it is recommended for people 60 and older. That's the shot George Green got.

Zostavax only cuts the risk of getting shingles in half and lasts about five years, the Centers for Disease Control and Prevention says. On Friday, the FDA licensed a second shingles vaccine, GlaxoSmithKline's Shingrix, which also uses a new additive. The vaccine committee is to decide whether to begin recommending it. Shingrix has been shown to be 90 percent effective and last at least four years in company-sponsored studies. Glaxo officials say they are confident it will last years longer. Experts say it will take many years to know for sure.

Explore further: Flu vaccine ineffective for people 65 and older last winter

Related Stories

Flu vaccine ineffective for people 65 and older last winter

June 21, 2017
The flu vaccine did a poor job protecting older Americans against the illness last winter, even though the vaccine was well-matched to the flu bugs going around.

Experts say flu season could be severe this year

September 22, 2017
If last year's active flu season and this year's severe season in the Southern Hemisphere is any indication of what flu season will look like across the country beginning this fall, then it's important to get vaccinated soon ...

Live attenuated flu vaccine not effective for children in 2015-16

August 10, 2017
(HealthDay)—During the 2015 to 2016 season, influenza vaccines reduced the risk of influenza illness, but the live attenuated vaccine was ineffective among children 2 to 17 years of age, according to a study published in ...

Panel gives weak endorsement of new meningitis shots

June 24, 2015
A federal panel has given a weak endorsement to two expensive new meningitis shots, declining to recommend the vaccines for all teens and leaving the decision to parents and doctors.

Heat blamed for spray vaccine's failure against swine flu

February 26, 2015
(AP)—The makers of the nasal spray version of the flu vaccine say now they know why it has failed to protect young U.S. children against swine flu—fragile doses got too warm.

Merck, Sanofi Pasteur ending JV to market vaccines in Europe

March 8, 2016
Merck and Sanofi Pasteur are ending their partnership, begun in 1994, to market the drugmakers' vaccines in Europe.

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.